The Radiobiology of Targeted Radiotherapy

References

• Barendsen G.W. Dose fractionation, dose-rate and isoeffect relationships for normal tissue responses. International Journal of Radiation Oncology, Biology, Physics 1982; 8: 1981–1997
   PubMed Web of Science ®Google Scholar
• Begent R.H.J., Green A.J., Bagshawe K.D., Jones B.E., Keep P.A., Searle F., Jewkes R.F., Barratt G.M. Liposomally entrapped second antibody improves tumour imaging with radiolabelled (first) antibody. Lancet 1982; ii: 739–742
   Google Scholar
• Begent R.H.J., Bagshawe K.D., Pedley R.B., Searle F., Lederman J.A., Green A.J., Keep P.A., Chester K.A., Glaser M.J., Dale R.G. Use of a second antibody in radioimmunotherapy. National Cancer Institute Monographs 1987; 3: 59–61
   Google Scholar
• Begent R.H.J., Ledermann A.J., Green A.J., Bagshawe K.D., Riggs S.J., Searle F., Keep P.A., Adam E.T., Dale R.G., Glaser M.G. Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer. British Journal of Cancer 1989; 60: 406–412
   PubMed Web of Science ®Google Scholar
• Bloomer W.D., McLauchlin W.H., Weichselbaum R.R., Hansan R.N., Adelstein S.J., Seitz D.E. The role of subcellular localisation in the cytotoxicity of 125I-labelled iododeoxyuridine, iodotamoxifen and iodoantipyrine. Journal of Radioanalytical Chemistry 1981; 65: 209–221
   Web of Science ®Google Scholar
• Bradley E.W., Chan P.C., Adelstein S.J. The radiotoxicity of iodine-125 in mammalian cells. I. Effects on survival curve of radioiodine incorporated into DNA. Radiation Research 1975; 64: 555–563
   PubMed Web of Science ®Google Scholar
• Brodsky F.M. Monoclonal antibodies as magic bullets. Pharmaceutical Research 1988; 5: 1–9
   PubMed Web of Science ®Google Scholar
• Burchiel S.W., Martin J.C., Imai K., Ferrore S., Warner N.L. Heterogeneity of HLA-A, B., la-like and melanoma associated antigen expression by human melanoma cell lines analysed with monoclonal antibodies and flow cytometry. Cancer Research 1982; 42: 4110–4115
   PubMed Web of Science ®Google Scholar
• Chan P.C., Lisco E., Lisco H., Adelstein S.J. The radiotoxicity of iodine-125 in mammalian cells. II. A comparative study on cell survival and cytogenetic responses to 125IUDR, 131IUDR and 3HTdr. Radiation Research 1976; 67: 332–343
   PubMed Web of Science ®Google Scholar
• Cobb L.M., Humm J.L. Radioimmunotherapy of malignancy using antibody targeted radionuclides. British Journal of Cancer 1986; 54: 863–870, 1986
   PubMedGoogle Scholar
• Cobb L.M., Harrison A., Dudley N.E., Carr T.E.G., Humphreys J.A. Relative concentrations of astatine-211 and iodine-125 by human fetal thyroid and carcinoma of the thyroid in nude mice. Radiotherapy and Oncology 1988; 13: 203–209
   PubMedGoogle Scholar
• Darte L., Tennvall J. Enhanced therapeutic tumour dose of 131I-mIBG by accelerated dieuresis. European Journal of Nuclear Medicine 1988; 14: 512–514
   PubMedGoogle Scholar
• Dale R.G. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. British Journal of Radiology 1985; 58: 515–528
   PubMed Web of Science ®Google Scholar
• Dale R.G. Time-dependent tumour repopulation factors in linear quadratic equations: implications for treatment strategies. Radiotherapy and Oncology 1989; 15: 371–382
   PubMed Web of Science ®Google Scholar
• Dale R.G., Huczowski J., Trott K.R. Possible dose rate dependence of recovery kinetics and deduced from a preliminary analysis of the effects of fractionated irradiations at varying dose rates. British Journal of Radiology 1988; 61: 153–157
   PubMed Web of Science ®Google Scholar
• de Nardo S.J., de Nardo G.L., O'Grady L.F., Levy L.F., Mills S.L., Macey D.J., McGrahan J.P., Miller C.H., Epstein A.L. Pilot studies of radioimmunotherapy of B cell lymphoma and leukaemia using 131I-lym-1 monoclonal antibody. Antibody Immunology and Radiopharmacology 1988; 1: 17–33
   PubMedGoogle Scholar
• Dillman L.T., von der Lage F.C. Radionuclide Decay Schemes and Nuclear Parameters for Use in Radiation Dose Estimation. Society of Nuclear Medicine, New York 1975, MIRD pamphlet 10
   Google Scholar
• Dische S., Saunders I.M. Continuous hyperfractionated accelerated radiotherapy (CHART). British Journal of Cancer 1989; 59: 325–326
   PubMedGoogle Scholar
• Douglas B.G., Fowler J.F. The effect of multiple small doses of X-rays on skin reactions in the mouse and a basic interpretation. Radiation Research 1976; 66: 401–426
   PubMed Web of Science ®Google Scholar
• Edwards P.A.W. Heterogeneous expression of cell surface antigens in normal epithelia and their tumours revealed by monoclonal antibodies. British Journal of Cancer 1985; 51: 149–160
   PubMed Web of Science ®Google Scholar
• Epenetos A.A., Kosmas C. Monoclonal antibodies for imaging and therapy. British Journal of Cancer 1989; 59: 152–155
   PubMed Web of Science ®Google Scholar
• Epenetos A.A., Hammersmith Hospital Oncology Group and Imperial Cancer Research Fund. Antibody-guided irradiation of malignant lesions: three cases illustrating a new method of treatment. Lancet 1984; ii: 1441–1443
   Google Scholar
• Feinendegen L.E. Biological damage from the Auger effect: possible benefits. Radiation and Environmental Biophysics 1975; 12: 85–99
   PubMed Web of Science ®Google Scholar
• Fertil B., Malaise E.P. Inherent cellular radiosensitivity as a basic concept for human tumour radiosensitivity. International Journal of Radiation Oncology, Biology, Physics 1981; 7: 621–629
   PubMed Web of Science ®Google Scholar
• Fowler J.F. The linear quadratic model and progress in fractionated radiotherapy. British Journal of Radiology 1989; 62: 679–694
   PubMed Web of Science ®Google Scholar
• Goldenberg D.M. Targeting of cancer with radiolabelled antibodies. Archives of Pathology and Laboratory Medicine 1988; 112: 580–587
   PubMed Web of Science ®Google Scholar
• Habermalz H.J., Bamberg M. The role of radiotherapy in paediatric oncology. Monographs in Paediatrics 1986; 18: 39–55
   Google Scholar
• Hagan P.L., Halpern S.G., Dillan R.O., Shawler D.L., Johnson D.E., Chen A., Krishman L., Frincke J., Bartholomew R.M., David G.S. Tumour size: effect on monoclonal antibody uptake in tumour models. Journal of Nuclear Medicine 1986; 27: 422–427
   PubMedGoogle Scholar
• Hall E.J. Radiobiology for the Radiologist3rd edn. J. P. Lippincott, Philadelphia 1988
   Google Scholar
• Hand P.H., Nuti M., Colcher D., Schlom J. Definition of antigenic heterogeneity and modulation amongst human mammary carcinoma cell populations using monoclonal antibodies to tumour-associated antigens. Cancer Research 1983; 43: 728–735
   PubMed Web of Science ®Google Scholar
• Harrison A., Royle L. Preparation of a 211At-IgG conjugate which is stable in vivo. International Journal of Applied Radiation and Isotopes 1984; 35: 1005–1008
   PubMedGoogle Scholar
• Harrison A., Royle L. Efficacy of Astatine-211 labelled monoclonal antibody in treatment of murine T-cell lymphoma. National Cancer Institute Monographs 1987; 3: 157–158
   Google Scholar
• Hartmann O., Lumbrosa J.D., Lemerle M., Schlumberger M., Ricard M., Aubert B., Coornaert S., Merlin L., Parmentier C. Therapeutic use of I-131 meta-iodo-benzyl-guanadine (mIBG) in neuroblastoma: a phase II study in 12 patients. Progress in Clinical and Biological Research 1988; 271: 655–667
   PubMedGoogle Scholar
• Hofer K.G. Radiation biology and the potential therapeutic applications of radionuclides. Bulletin of Cancer 1980; 67: 343–353
   PubMed Web of Science ®Google Scholar
• Hofer K.G., Hughes W.L. Radiotoxicity of intranuclear tritium, 125iodine and 131iodine. Radiation Research 1971; 47: 94–109
   PubMed Web of Science ®Google Scholar
• Huczkowski J., Trott K.R. Dose fractionation effects in low dose rate irradiation of jejunal crypt stem cells. International Journal of Radiation Biology 1984; 46: 293–298
   Web of Science ®Google Scholar
• Huczkowski J., Trott K.R. Jejunal crypt stem cells survival after fractionated irradiation performed at different dose rates. International Journal of Radiation Biology 1987; 51: 131–138
   Web of Science ®Google Scholar
• Humm J.L. Dosimetric aspects of radiolabelled antibodies for tumour therapy. Journal of Nuclear Medicine 1986; 9: 1490–1497
   Google Scholar
• Humm J.L., Charlton D.E. Theoretical estimates of strand breakage resulting from the decay of 125I appended to DNA by intermediate molecules (Abstract). Radiation Research: Proceedings of the 8th International Congress of Radiation Research, E.M. Fielden, J.F. Fowler, J.H. Hendry, D. Scott. Taylor & Francis, London 1987; 68–68
   Google Scholar
• Kassis A.I., Adelstein S.J., Howell R.W., Sastry K.S.R. Positional effects of Auger emitters in mammalian cells. DNA Damage by Auger Emitters, K.F. Baverstock, D.E. Charlton. Taylor & Francis, London 1988; 1–12
   Google Scholar
• Kassis A.I., Fahed F., Kinsey B., Sastry K.S.R., Adelstein S.J. Radiotoxicity of an 125I-labelled DNA intercalator in mammalian cells. Radiation Research 1989; 118: 283–294
   PubMed Web of Science ®Google Scholar
• Kozak R.W., Atcher R.W., Gansow O.A., Friedman A.M., Hines J., Waldmann T.A. Bismuth-212-labelled anti-tac monoclonal antibody: α-particle emitting radionuclides as modalities for radioimmunotherapy. Proceedings of the National Academy of Sciences, USA 1986; 83: 474–487
   PubMed Web of Science ®Google Scholar
• Kumar R., Barbacid M. Oncogene detection at the single cell level. Oncogene 1988; 3: 647–651
   PubMed Web of Science ®Google Scholar
• Langmuir V.K., McGann J.K., Buchegger F., Sutherland R.M. 131I-Anticarcinoembryonic antigen therapy of LS174T human colon adenocarcinoma spheroids. Cancer Research 1989; 49: 3401–3406
   PubMed Web of Science ®Google Scholar
• Larson S.M. Radiolabelled monoclonal antitumour antibodies in diagnosis and therapy. Journal of Nuclear Medicine 1985; 26: 538–545
   PubMed Web of Science ®Google Scholar
• Lashford L.S., Moyes J., Ott R., Fielding S., Babich J., Mellors S., Gordon I. The biodistribution and pharmacokinetics of meta-iodo-benzyl-guanidine in children with neuroblastoma. European Journal of Nuclear Medicine 1988a; 13: 574–577
   PubMedGoogle Scholar
• Lashford L.S., Davies A.G., Richardson R.B., Bourne S.B., Bullimore J.A., Eckert H., Kemshead J.T., Coakham H.B. A pilot study of 131I monoclonal antibodies in the therapy of lepto meningeal tumours. Cancer 1988b; 61: 857–868
   PubMed Web of Science ®Google Scholar
• Lee M.S., Chang K.S., Cabinalls F., Freireich E.J., Trujillo J.M., Stass S.A. Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science 1987; 237: 175–178
   PubMed Web of Science ®Google Scholar
• Leichner P.K., Yang N.C., Frenkel T.L., Loudenslarger D.M., Hawkins W.G., Klein G.L. Dosimetry and treatment planning for 90Y-labelled antiferritin in hepatoma. International Journal of Radiation Oncology, Biology, Physics 1988; 14: 1033–1042
   PubMed Web of Science ®Google Scholar
• Lenhard R.E., Order S.E., Spunberg J.J., Asbell S.O., Leibel A.S. Isotopic immunoglobin: a new systemic therapy for advanced Hodgkin's disease. Journal of Clinical Oncology 1985; 3: 1296–1300
   PubMed Web of Science ®Google Scholar
• Leibel S.A. Targeted radionuclides. Innovations in Radiation Oncology, H.R. Withers, L.J. Peters. Springer Verlag, Berlin 1988; 129–140
   Google Scholar
• Link E.M., Brown I., Carpenter R.N., Mitchell J.S. Uptake and therapeutic effectiveness of 125I- and 211At-methylene blue for pigmented melanoma in an animal model system. Cancer Research 1989; 49: 4332–4337
   PubMed Web of Science ®Google Scholar
• Ljunberg M., Strand S.E. Dose planning with SPECT. International Journal of Cancer 1988, 2: 67–70
   Google Scholar
• McFadden R., Kwok C.S. Mathematical model of simultaneous diffusion and binding of antibodies in multicellular human tumour spheroids. Cancer Research 1988; 48: 4032–4037
   PubMed Web of Science ®Google Scholar
• McManaway M.E., Jagoda E.M., Eckelman W.C., Larson S.M., Francis B.E., Gibson R.E., Reba R.C., Lippman M.E. Binding characteristics and biological activity of 17α-[125I]iodovinyl-11β-methoxyestradiol, an oestrogen receptor binding radiopharmaceutical in human breast cancer cells (MCF-7). Cancer Research 1986; 46: 2386–2389
   PubMedGoogle Scholar
• Mitchell J.S. Attempts to develop radioactive drugs in the treatment of cancer. Radiotracer Techniques and Applications, E.A. Evans, M. Muramatsu. Marcel Dekker, New York 1977; 1081–1110
   Google Scholar
• Morgan G.J., Janssen S.W.G., Guo A.P., Wiedman L.M., Hughes T., Gow J., Goldman J.M., Bartram C.R. Polymerase chain reaction for detection of residual leukaemia. Lancet 1989; i: 928–929
   Google Scholar
• Moyes J.S.E., Babich J.W., Carter R., Meller S.T., Agrawal M., McElwain T.J. A quantitative study of meta-iodobenzylguanidine (mIBG) uptake in children with neuroblastoma: correlation with tumour histopathology. Journal of Nuclear Medicine 1989; 30: 474–480
   PubMed Web of Science ®Google Scholar
• Munro T.R., Gilbert C.W. The relation between tumour lethal dose and the radiosensitivity of tumour cells. British Journal of Radiology 1961; 34: 246–251
   PubMed Web of Science ®Google Scholar
• Myers M.J. Dosimetry for radiolabelled antibodies: macro or micro. International Journal of Cancer 1988, 2: 71–73
   PubMedGoogle Scholar
• Olander K., Larsson B., Dencker L. Thioamides as false melanin precursors: studies in murine melanomas. Acta Pharmacologica et Toxicologica 1983; 52: 135–142
   PubMedGoogle Scholar
• Order S.E., Klein J.L., Ettinger D.S., Alderson P., Siegelman S., Leichner P.K. Phase I–II study of radiolabelled antibody integrated in the treatment of primary hepatic malignancies. International Journal of Radiation Oncology, Biology, Physics 1980a; 6: 703–710
   PubMed Web of Science ®Google Scholar
• Order S.E., Klein J.L., Ettinger D., Alderson P., Siegelman S., Leichner P. Use of isotopic immunoglobulin in therapy. Oncology 1980b; 38: 154–160
   Google Scholar
• O'Donoghue J.A., Wheldon T.E. Predicted allowable doses to normal organs for biologically targeted radiotherapy. British Journal of Radiology 1988; 61: 264–266
   PubMed Web of Science ®Google Scholar
• O'Donoghue J.A., Wheldon T.E. Dose rate effects in biologically targeted radiotherapy. International Journal of Radiation Biology 1989; 56: 745–749
   PubMed Web of Science ®Google Scholar
• Pectasides D., Stewart S., Courtney-Luck N., Rampling R., Munro A., Krauz T., Dhokia B., Snook D., Hooker G., Durbin H. Antibody-guided irradiation of malignant pleural and pericardial effusions. British Journal of Cancer 1986; 53: 727–732
   PubMed Web of Science ®Google Scholar
• Pervez S., Kirkland S.C., Epenetos A.A., Mooi W.J., Evans D.J., Krausz T. Effect of polarity and differentiation on antibody localisation in multicellular tumour spheroid and xenograft models and its potential importance for in vivo immunotargeting. International Journal of Cancer 1989; 44: 940–947
   PubMed Web of Science ®Google Scholar
• Peters L.J., Ang K.K., Thames H.D. Accelerated fractionation in the treatment of head and neck cancer: a critical comparison of different strategies. Acta Oncologica 1988; 27: 185–194
   PubMed Web of Science ®Google Scholar
• Pimm M.V., Baldwin R.W. Distribution of IgM monoclonal antibody in mice with human tumour xenografts: lack of tumour localisation. European Journal of Cancer and Clinical Oncology 1985; 6: 765–768
   Google Scholar
• Porter E.H. The statistics of dose-cure relationships for irradiated tumours. Part 1. British Journal of Radiology 1980; 53: 210–227
   PubMedGoogle Scholar
• Raso V. Antibody mediated delivery of toxic molecules to antigen bearing cells. Immunology Reviews 1982; 62: 93–117
   PubMedGoogle Scholar
• Riggs S.J., Green A.J., Begent R.H.J., Bagshawe K.D. Quantitation in 131I radioimmunotherapy using SPECT. International Journal of Cancer 1988, 2: 95–98
   Google Scholar
• Roesch W.C. Models of the radiation sensitivity of mammalian cells. Proceedings of the Third Symposium on Neutron Dosimetry in Biology and Medicine, G. Burger, H.G. Ebert. Commission of the European Communities, Luxembourg 1978; 1–27
   Google Scholar
• Rojas A., Joiner M.C. The influence of dose per fraction on repair kinetics. Radiotherapy and Oncology 1989; 14: 329–336
   PubMed Web of Science ®Google Scholar
• Rosen S.T., Zimmer M., Goldman-Leiken R., Gordon L.I., Kazikiewicz J.M., Kaplan E.H., Variakojis D., Marder R.J., Dykewicz M.S., Piergies A. Radioimmunodetection and radioimmunotherapy of cutaneous T-cell lymphomas using a 131I-labelled monoclonal antibody: an Illinois Cancer Council study. Journal of Clinical Oncology 1987; 5: 562–573
   PubMed Web of Science ®Google Scholar
• Sikora K., Smedley H.M. Monoclonal Antibodies. Blackwell, Oxford 1984
   Google Scholar
• Steel G.G. Growth Kinetics of Tumours. Clarenden Press, Oxford 1977
   Google Scholar
• Steel G.G., Deacon J.M., Duchesne G.M., Horwich A., Kelland L.R., Peacock J.H. The dose-rate effect in human tumour cells. Radiotherapy and Oncology 1987; 9: 299–310
   PubMed Web of Science ®Google Scholar
• Stephens T.C., Eady J.J., Peacock J.H., Steel G.G. Split-dose and low dose-rate recovery in four experimental tumour systems. International Journal of Radiation Biology 1987; 52: 157–170
   Web of Science ®Google Scholar
• Stewart F.A., Oussoren Y., Luts A., Begg A.C., Dewit L., Lebesque J., Bartelink H. Repair of sublethal radiation injury after multiple small doses in mouse kidney: an estimate of flexure dose. International Journal of Radiation Oncology, Biology, Physics 1987; 13: 765–772
   PubMed Web of Science ®Google Scholar
• Stewart J.S.W., Hird V., Snook D., Sullivan M., Myers M.J., Epenetos A.A. Interperitoneal 131I and 90Y labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry. International Journal of Cancer 1988, 3: 71–76
   PubMedGoogle Scholar
• Stewart, J.S.W., Hird, V., Snook, D., Sullivan, M., Hooker, G., et al. Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity and efficacy of 131I labelled monoclonal antibodies. International Journal of Radiation Oncology, Biology, Physics 1989; 16: 405–413
   PubMed Web of Science ®Google Scholar
• Sutherland R., Buchegger F., Schreyer M., Vacca A., Mach J.P. Penetration and binding of radiolabelled anti-carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular spheroids. Cancer Research 1987; 47: 1627–1633
   PubMedGoogle Scholar
• Thames H.D. An ‘incomplete repair’ model for survival after fractionated and continuous irradiations. International Journal of Radiation Biology 1985; 47: 319–339
   Web of Science ®Google Scholar
• Thames H.D., Hendry J.H. Fractionation in Radiotherapy. Taylor & Francis, London 1987
   Google Scholar
• Thames H.D., Withers H.R., Peters L.J., Fletcher G.H. Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. International Journal of Radiation Oncology, Biology, Physics 1982; 8: 219–226
   PubMed Web of Science ®Google Scholar
• Thames H.D., Peters L.J., Withers H.R., Fletcher G.H. Accelerated fractionation vs hyperfractionation: rationales for several treatments per day. International Journal of Radiation Oncology, Biology, Physics 1983; 9: 127–138
   PubMed Web of Science ®Google Scholar
• Thames H.D., Withers H.R., Peters L.J. Tissue repair capacity and repair kinetics deduced from multifractionated or continuous irradiation regimens with incomplete repair. British Journal of Cancer 1984; 49(VI)263–269
   PubMed Web of Science ®Google Scholar
• Thames H.D., Ang K.K., Stewart F.A., van der Schueren E. Does incomplete repair explain the apparent failure of the basic LQ model to predict spinal cord and kidney responses to low doses per fraction. International Journal of Radiation Biology 1988; 54: 13–19
   PubMed Web of Science ®Google Scholar
• Travis E., Tucker S. Isoeffect models and fractionated radiotherapy. International Journal of Radiation Oncology, Biology, Physics 1987; 13: 283–287
   PubMedGoogle Scholar
• Treuner J., Gerein V., Klingebiegel T., Schwabe D., Feine U., Happ J., Niethammer D., Maul F., Dopfer R., Kornhuber B. mIBG treatment in neuroblastoma: experiences of the Tubingen/Frankfurt group. Progress in Clinical and Biological Research 1988; 271: 669–678
   PubMedGoogle Scholar
• Trott K.R., Kummermehr J. What is known about tumour proliferation rates to choose between accelerated fractionation or hyperfractionation?. Radiotherapy and Oncology 1985; 3: 1–9
   PubMed Web of Science ®Google Scholar
• Vaughan A.T.M., Bateman W.J., Brown G., Cowan J. The specific inhibition of cellular clonogenic proliferation using 211At labelled lectins and antibodies. International Journal of Nuclear Medicine and Biology 1982; 9: 167–171
   PubMedGoogle Scholar
• Vaughan A.T.M., Anderson P., Dykes P., Bradwell A.R. Limitations to killing of tumours using radiolabelled antibodies. British Journal of Radiology 1987; 60: 567–578
   PubMed Web of Science ®Google Scholar
• Vriesendrop H.M., Herpst J.M., Leichner P.K., Klein J.L., Order S.E. Polyclonal 90Y labelled antiferritin for refractory Hodgkin's disease. International Journal of Radiation Oncology, Biology, Physics 1989; 17: 815–821
   PubMedGoogle Scholar
• Walker K.A., Murray T., Hilditch T.E., Wheldon T.E., Hann I.M. A tumour spheroid model for antibody-targeted therapy of micrometastases. British Journal of Cancer 1988; 58: 13–16
   PubMedGoogle Scholar
• Ward B., Mather S., Shepherd J., Crowther M., Hawkins L., Britten K., Slevin M.L. The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy. British Journal of Cancer 1988; 58: 658–662
   PubMed Web of Science ®Google Scholar
• Wessels B.W., Rogus K.D. Radionuclide selection and model absorbed dose calculations for radiolabelled tumour associated antibodies. Medical Physics 1984; 11: 638–644
   PubMed Web of Science ®Google Scholar
• Wessels B.W., Vessella R.L., Palme D.F., Berkopek J.M., Smith G.K., Bradley E.W. Radiobiological comparison of external beam irradiation and radioimmunotherapy in renal cell carcinoma xenografts. International Journal of Radiation Oncology, Biology, Physics 1989, in press
   PubMedGoogle Scholar
• Wheldon T.E., Amin A.E. The linear quadratic model. British Journal of Radiology 1988; 61: 700–702
   PubMedGoogle Scholar
• Wheldon T.E., O'Donoghue J.A., Hilditch T.E., Barrett A. Strategies for systemic radiotherapy of micrometastases using antibody-targeted 131I. Radiotherapy and Oncology 1988; 11: 133–142
   PubMedGoogle Scholar
• Williams M.V., Denekamp J., Fowler J.F. A review of α/β ratios for experimental tumours: implications for clinical studies of altered fractionation. International Journal of Radiation Oncology, Biology, Physics 1985; 11: 87–96
   PubMed Web of Science ®Google Scholar
• Woo D.V., Li D., Mattis J.A., Steplewski Z. Selective chromosome damage and cytotoxicity of 125I-labelled monoclonal antibody 17-la in human cancer cells. Cancer Research 1989; 49: 2952–2958
   PubMed Web of Science ®Google Scholar
• Yorke E.D., Griffith M.H., Wessels B.W. Quantitative autoradiography and micro-TLD measurements for radioimmunotherapy. Journal of Nuclear Medicine 1987; 28: 617–617
   Google Scholar